- Home
- PNI vs SLGL Comparison
PNI vs SLGL Comparison
Compare PNI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- SLGL
- Stock Information
- Founded
- PNI 2002
- SLGL 1997
- Country
- PNI United States
- SLGL Israel
- Employees
- PNI N/A
- SLGL N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- SLGL Health Care
- Exchange
- PNI Nasdaq
- SLGL Nasdaq
- Market Cap
- PNI 77.2M
- SLGL 69.1M
- IPO Year
- PNI N/A
- SLGL 2018
- Fundamental
- Price
- PNI $6.95
- SLGL $24.35
- Analyst Decision
- PNI
- SLGL
- Analyst Count
- PNI 0
- SLGL 0
- Target Price
- PNI N/A
- SLGL N/A
- AVG Volume (30 Days)
- PNI 26.4K
- SLGL 32.4K
- Earning Date
- PNI 01-01-0001
- SLGL 11-14-2025
- Dividend Yield
- PNI 4.76%
- SLGL N/A
- EPS Growth
- PNI N/A
- SLGL N/A
- EPS
- PNI N/A
- SLGL N/A
- Revenue
- PNI N/A
- SLGL $23,931,000.00
- Revenue This Year
- PNI N/A
- SLGL N/A
- Revenue Next Year
- PNI N/A
- SLGL $31.17
- P/E Ratio
- PNI N/A
- SLGL N/A
- Revenue Growth
- PNI N/A
- SLGL 264.86
- 52 Week Low
- PNI $6.03
- SLGL $4.01
- 52 Week High
- PNI $7.89
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- PNI 73.75
- SLGL 59.60
- Support Level
- PNI $6.49
- SLGL $23.13
- Resistance Level
- PNI $6.93
- SLGL $24.85
- Average True Range (ATR)
- PNI 0.07
- SLGL 2.20
- MACD
- PNI 0.03
- SLGL -0.53
- Stochastic Oscillator
- PNI 90.49
- SLGL 37.22
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.